Phosphodiesterase Inhibitors Could Reverse the Proliferation of BPH Epithelial Cells Induced by CD8+ T Cells in Low Androgen Condition
April 2018
in “
The Journal of Urology
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → Studysummary This study found that phosphodiesterase inhibitors may suppress the proliferation of benign prostatic hyperplasia epithelial cells by modulating CCL5 levels in low androgen conditions.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study demonstrated that phosphodiesterase inhibitors (PDE5Is), specifically tadalafil, could reverse the proliferation of benign prostatic hyperplasia (BPH) epithelial cells induced by CD8+ T cells in low androgen conditions. This effect was mediated through the cGMP/PKG signaling pathway. The research involved 36 TURP prostate specimens, with 18 treated with finasteride and 18 untreated. Results showed that PDE5 protein was over-expressed in the finasteride group, and tadalafil significantly reduced CCL5 levels in co-cultured BPH-1 and CD8+ T cells. The findings suggested that combining 5α-reductase inhibitors with PDE5Is might be beneficial for BPH patients.
